Oddity Tech Q1 2026: Revenue Plunges 26% YoY, Posts Adjusted EBITDA Loss

What happened

Oddity Tech reported a disastrous first quarter of 2026, with net revenue of $197.9 million, down approximately 26% year-over-year, and an adjusted EBITDA loss of $7.0 million, compared to a profit a year ago. The company also posted a net loss of $21.4 million and an adjusted net loss of $9.8 million, a stark reversal from prior profitability. Management framed this as 'progress toward normalization,' suggesting that the prior year's results were artificially inflated, possibly by a one-time boost from the Methodiq launch or other factors. However, the magnitude of the decline—far exceeding the base case of ~20% growth assumed in the DeepValue report—signals a fundamental deterioration in the business. The balance sheet remains strong with $667.4 million in cash and an undrawn $350 million credit facility, but the operating collapse raises serious questions about the sustainability of the DTC beauty model.

Implication

The Q1 2026 results completely invalidate the investment thesis laid out in the DeepValue report, which assumed continued ~20% revenue growth and ~20% adjusted EBITDA margins. Instead, revenue fell 26% and adjusted EBITDA turned negative, signaling a collapse in unit economics or a severe demand shock. The 'normalization' narrative is a red flag—it implies that prior growth was unsustainable and that the company is now resetting to a much lower baseline. Given the overnight destruction of the growth story and the lack of any margin floor, there is no basis for holding the stock at current valuations. Even though the balance sheet is cash-rich, the enterprise is burning cash and has lost its growth premium. Investors should sell into any bounce and avoid until there is concrete evidence that the business can stabilize, let alone return to its prior trajectory. The bear case from the DeepValue report—$28 per share—now looks optimistic; a more realistic scenario is a further decline to single-digit multiples of a severely shrunken earnings base.

Thesis delta

The investment thesis is broken. The expectation of 20%+ revenue growth and ~20% EBITDA margins has been replaced by a 26% revenue decline and negative EBITDA. The 'normalization' framing suggests management is managing down expectations, but the data point to a structural deterioration, not a temporary hiccup. The thesis has shifted from 'potential buy at $36' to 'clear sell at any price above cash value.'